Kronos Bio, Inc. (KRON)
NASDAQ
Market Cap
$57.22M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
72 of 809
Rank in Industry
57 of 445
Largest Insider Buys in Sector
KRON Stock Price History Chart
KRON Stock Performance
About Kronos Bio, Inc.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Insider Activity of Kronos Bio, Inc.
Over the last 12 months, insiders at Kronos Bio, Inc. have bought $4.59M and sold $151,964 worth of Kronos Bio, Inc. stock.
On average, over the past 5 years, insiders at Kronos Bio, Inc. have bought $16.99M and sold $1.93M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BISCHOFBERGER NORBERT W (President & CEO) — $9.18M.
The last purchase of 881,913 shares for transaction amount of $1.1M was made by BISCHOFBERGER NORBERT W (PRESIDENT & CEO) on 2024‑06‑12.
List of Insider Buy and Sell Transactions, Kronos Bio, Inc.
| 2024-06-12 | BISCHOFBERGER NORBERT W | PRESIDENT & CEO | 881,913 1.586% | $1.24 | $1.1M | -18.75% | ||
| 2024-06-11 | BISCHOFBERGER NORBERT W | PRESIDENT & CEO | 744,308 1.1787% | $1.09 | $814,571 | -9.57% | ||
| 2024-06-10 | BISCHOFBERGER NORBERT W | PRESIDENT & CEO | 1.38M 2.1146% | $0.88 | $1.21M | +10.41% | ||
| 2024-02-21 | Sale | Lin Charles Y | SR VP, RESEARCH & DEVELOPMENT | 12,036 0.0205% | $1.05 | $12,685 | -0.95% | |
| 2024-02-21 | Sale | Frisbee Allison | SR VP, CORP OPERATIONS & LEGAL | 12,105 0.0206% | $1.05 | $12,757 | -0.95% | |
| 2024-02-21 | Sale | Olek Elizabeth A | SR VP, CLINICAL SCIENCE | 7,368 0.0126% | $1.05 | $7,765 | -0.95% | |
| 2024-01-04 | Sale | Kosacz Barbara | COO & General Counsel | 10,676 0.0179% | $1.18 | $12,636 | -11.57% | |
| 2024-01-04 | Sale | DiMartino Jorge | Chief Medical Officer & VP | 12,009 0.0201% | $1.18 | $14,214 | -11.57% | |
| 2024-01-04 | Sale | Dinsmore Christopher | Chief Scientific Officer | 7,366 0.0124% | $1.18 | $8,718 | -11.57% | |
| 2023-12-12 | Sale | DiMartino Jorge | Chief Medical Officer & VP | 17,367 0.0299% | $1.30 | $22,664 | -16.15% | |
| 2023-12-12 | Sale | Dinsmore Christopher | Chief Scientific Officer | 10,032 0.0173% | $1.30 | $13,092 | -16.15% | |
| 2023-11-17 | BISCHOFBERGER NORBERT W | President & CEO | 97,935 0.167% | $1.08 | $106,162 | +3.70% | ||
| 2023-11-16 | BISCHOFBERGER NORBERT W | President & CEO | 262,433 0.4271% | $1.00 | $261,514 | +6.16% | ||
| 2023-11-15 | BISCHOFBERGER NORBERT W | President & CEO | 1.37M 2.1008% | $0.80 | $1.1M | +24.43% | ||
| 2023-07-06 | Sale | Al-Wakeel Yasir B. | Chief Financial Officer | 9,617 0.0159% | $1.75 | $16,852 | -36.56% | |
| 2023-07-06 | Sale | DiMartino Jorge | Chief Medical Officer & VP | 10,818 0.0178% | $1.75 | $18,956 | -36.56% | |
| 2023-07-06 | Sale | Dinsmore Christopher | Chief Scientific Officer | 6,634 0.0109% | $1.75 | $11,625 | -36.56% | |
| 2023-02-24 | Sale | Al-Wakeel Yasir B. | Chief Financial Officer | 9,026 0.0167% | $1.74 | $15,665 | -19.76% | |
| 2023-02-24 | Sale | DiMartino Jorge | Chief Medical Officer & VP | 10,153 0.0188% | $1.74 | $17,621 | -19.76% | |
| 2023-02-24 | Sale | Dinsmore Christopher | Chief Scientific Officer | 6,291 0.0116% | $1.74 | $10,918 | -19.76% |
Insider Historical Profitability
<0.0001%
| BISCHOFBERGER NORBERT W | President & CEO | 7375616 4.3567% | $0.95 | 9 | 0 | <0.0001% |
| Kosacz Barbara | COO & General Counsel | 928966 1.593% | $0.95 | 1 | 1 | <0.0001% |
| Al-Wakeel Yasir B. | Chief Financial Officer | 346102 0.5935% | $0.95 | 1 | 2 | <0.0001% |
| DiMartino Jorge | Chief Medical Officer & VP | 315246 0.5406% | $0.95 | 0 | 6 | |
| Dinsmore Christopher | Chief Scientific Officer | 260969 0.4475% | $0.95 | 1 | 9 | <0.0001% |
| Lin Charles Y | SR VP, RESEARCH & DEVELOPMENT | 234603 0.4023% | $0.95 | 0 | 1 | |
| Frisbee Allison | SR VP, CORP OPERATIONS & LEGAL | 204510 0.3507% | $0.95 | 0 | 1 | |
| Olek Elizabeth A | SR VP, CLINICAL SCIENCE | 193275 0.3314% | $0.95 | 0 | 1 | |
| Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust | 10 percent owner | 4370496 7.4944% | $0.95 | 1 | 0 | <0.0001% |
| Omega Fund V, L.P. | 10 percent owner | 3818283 6.5475% | $0.95 | 1 | 0 | <0.0001% |
| Stampacchia Otello | 3818283 6.5475% | $0.95 | 1 | 0 | <0.0001% | |
| MARTIN JOHN C | director | 1952364 3.3479% | $0.95 | 1 | 0 | <0.0001% |
| Loven Jakob | director | 1301537 2.2319% | $0.95 | 0 | 9 | |
| De Backer Marianne | director | 2750 0.0047% | $0.95 | 3 | 0 | <0.0001% |
| Ridloff Elena | director | 2630 0.0045% | $0.95 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Bvf Inc Il | $3.78M | 4.83 | 2.91M | 0% | +$0 | 0.03 | |
| Vida Ventures Advisors Llc | $3.59M | 4.6 | 2.77M | 0% | +$0 | 2 | |
| The Vanguard Group | $2.53M | 3.24 | 1.95M | +14.58% | +$322,293.34 | <0.0001 | |
| Millennium Management LLC | $2.38M | 3.04 | 1.83M | +115.53% | +$1.27M | <0.01 | |
| Alphabet | $1.87M | 2.39 | 1.44M | 0% | +$0 | 0.08 | |
| Wildcat Capital Management | $1.69M | 2.16 | 1.3M | 0% | +$0 | 0.61 | |
| Renaissance Technologies | $1.34M | 1.72 | 1.03M | +12.99% | +$154,186.46 | <0.01 | |
| Omega Fund Management Llc | $1.24M | 1.59 | 955,866 | -74.97% | -$3.72M | 0.92 | |
| BlackRock | $1.18M | 1.51 | 909,450 | -14.89% | -$206,770.38 | <0.0001 | |
| Artal Group S A | $1.1M | 1.4 | 842,954 | 0% | +$0 | 0.01 | |
| Acadian Asset Management | $1M | 1.29 | 774,559 | +17.19% | +$147,420.78 | <0.01 | |
| Partners Capital Investment Group Llp | $685,750.00 | 0.88 | 527,500 | -68.33% | -$1.48M | 0.03 | |
| Acuitas Investments, LLC | $573,438.00 | 0.73 | 441,106 | +34.49% | +$147,069.05 | 0.3 | |
| Geode Capital Management | $573,741.00 | 0.73 | 441,225 | +2.96% | +$16,518.17 | <0.0001 | |
| Cerity Partners | $534,034.00 | 0.68 | 410,796 | 0% | +$0 | <0.01 | |
| Bridgeway Capital Management | $409,503.00 | 0.52 | 315,002 | +7.26% | +$27,725.13 | 0.01 | |
| Choate Investment Advisors | $401,306.00 | 0.51 | 308,697 | 0% | +$0 | 0.01 | |
| Cm Management Llc | $325,000.00 | 0.42 | 250,000 | 0% | +$0 | 0.02 | |
| Two Sigma Advisers LP | $275,340.00 | 0.35 | 211,800 | -1.35% | -$3,770.00 | <0.0001 | |
| Citadel Advisors LLC | $246,232.00 | 0.32 | 189,409 | -4.32% | -$11,116.31 | <0.0001 | |
| State Street | $231,791.00 | 0.3 | 178,301 | 0% | +$0 | <0.0001 | |
| Two Sigma | $172,016.00 | 0.22 | 132,320 | -4.26% | -$7,660.90 | <0.0001 | |
| Casdin Capital | $160,991.00 | 0.21 | 123,839 | 0% | +$0 | 0.01 | |
| Kennedy Capital Management Inc | $149,579.00 | 0.19 | 115,061 | +6.31% | +$8,881.58 | <0.01 | |
| Squarepoint Ops LLC | $140,080.00 | 0.18 | 107,754 | -29.77% | -$59,368.32 | <0.01 | |
| Tealwood Asset Management | $104,480.00 | 0.13 | 80,369 | +19.77% | +$17,249.75 | 0.02 | |
| Mariner Llc | $102,440.00 | 0.13 | 78,800 | New | +$102,440.00 | <0.0001 | |
| Samsara Biocapital Llc | $101,570.00 | 0.13 | 78,131 | 0% | +$0 | 0.02 | |
| Forefront Analytics | $100,271.00 | 0.13 | 77,131 | +56.87% | +$36,352.15 | 0.05 | |
| Northern Trust | $98,315.00 | 0.13 | 75,627 | -18.39% | -$22,159.78 | <0.0001 | |
| Jacobs Levy Equity Management | $77,217.00 | 0.1 | 59,398 | -79.76% | -$304,370.02 | <0.0001 | |
| Gsa Capital Partners Llp | $75,000.00 | 0.1 | 57,347 | +128.06% | +$42,113.36 | 0.01 | |
| Virtu Financial Llc | $71,000.00 | 0.09 | 54,592 | New | +$71,000.00 | 0.01 | |
| Coastal Bridge Advisors Llc | $67,558.00 | 0.09 | 51,968 | 0% | +$0 | 0.02 | |
| Cornercap Investment Counsel Inc | $53,756.00 | 0.07 | 41,351 | 0% | +$0 | 0.01 | |
| Xtx Topco Ltd | $53,060.00 | 0.07 | 40,815 | +27.42% | +$11,418.01 | <0.01 | |
| HSBC | $49,878.00 | 0.06 | 38,368 | 0% | +$0 | <0.0001 | |
| Morgan Stanley | $49,189.00 | 0.06 | 37,837 | -1.82% | -$910.02 | <0.0001 | |
| Cubist Systematic Strategies | $39,378.00 | 0.05 | 30,291 | New | +$39,378.00 | <0.0001 | |
| Bluefin Trading, LLC | $32,630.00 | 0.04 | 25,100 | 0% | +$0 | 0.01 | |
| UBS | $26,839.00 | 0.03 | 20,645 | New | +$26,839.00 | <0.0001 | |
| Jane Street Capital | $23,932.00 | 0.03 | 18,409 | -3.51% | -$871.01 | <0.0001 | |
| Goldman Sachs | $23,264.00 | 0.03 | 17,895 | -8.9% | -$2,272.45 | <0.0001 | |
| Barclays | $21,000.00 | 0.03 | 16,128 | 0% | +$0 | <0.0001 | |
| Tower Research Capital | $19,746.00 | 0.03 | 15,189 | +20,995.83% | +$19,652.40 | <0.0001 | |
| Point72 Asia Singapore Pte Ltd | $15,920.00 | 0.02 | 12,246 | New | +$15,920.00 | <0.01 | |
| Bank of America | $7,468.00 | 0.01 | 5,744 | -0.5% | -$37.70 | <0.0001 | |
| Simplex Trading Llc | $6,000.00 | 0.01 | 5,190 | +651.09% | +$5,201.16 | <0.0001 | |
| Fidelity Investments | $4,160.00 | 0.01 | 3,200 | -99.12% | -$470,600.00 | <0.0001 | |
| RhumbLine Advisers | $2,714.00 | <0.01 | 2,088 | 0% | +$0 | <0.0001 |